Ticagrelor contraindications: Difference between revisions
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) |
||
| Line 19: | Line 19: | ||
====Hypersensitivity==== | ====Hypersensitivity==== | ||
BRILINTA is contraindicated in patients with hypersensitivity (e.g. [[angioedema]]) to ticagrelor or any component of the product [see Adverse Reactions | BRILINTA is contraindicated in patients with [[hypersensitivity]] (e.g. [[angioedema]]) to ticagrelor or any component of the product [see [[Ticagrelor adverse reactions|Adverse Reactions]]]''.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 22:56, 11 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Contraindications
History of Intracranial Hemorrhage
BRILINTA is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies].
Active Bleeding
BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see Warnings and Precautions and Adverse Reactions].
Severe Hepatic Impairment
BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins [see Clinical Pharmacology].
Hypersensitivity
BRILINTA is contraindicated in patients with hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product [see Adverse Reactions].[1]